TransMedics Group, Inc. 8-K

What Happened

• TransMedics Group, Inc. (TMDX) filed an 8-K reporting executive changes. On February 1, 2026 the Board appointed Giovanni Cecere as Chief Commercial Officer, effective February 2, 2026; he succeeds Tamer Khayal, M.D., who will become Senior Vice President of International effective the same date. The Board also appointed Matthew Forsyth as Senior Vice President, General Counsel & Corporate Secretary effective March 9, 2026 (or the first date of his employment if later).
• Current General Counsel Anil Ranganath will move to a non-executive role on the GC Transition Date and, under a Transition Agreement dated February 3, 2026, will remain a non-executive employee through June 7, 2026 and then serve as a non-employee consultant until September 7, 2026.

Key Details

• Giovanni Cecere becomes CCO effective February 2, 2026; Tamer Khayal shifts to SVP, International effective February 2, 2026.
• Matthew Forsyth’s GC appointment effective March 9, 2026 (or start date if later).
• Ranganath will: continue base salary as a non-exec employee, be eligible for his target 2025 bonus, have equity awards continue to vest during employment and consulting periods, and receive a $10,000 annualized consulting fee while a consultant.
• Post-Separation payments to Ranganath include: 0.75 × (his highest annual base salary in the prior 3 years + his highest annual bonus in the prior 3 years), COBRA premiums up to nine months, and a pro-rated 2026 bonus based on 2025 — subject to a release and compliance obligations.

Why It Matters

• These are material leadership changes in TransMedics’ commercial and legal functions that could affect commercial execution and legal oversight. The filing lays out timing, continuity measures (extended vesting and consulting), and the cash/benefit obligations tied to the GC transition, which are quantifiable near-term costs and ensure an orderly handover. Investors should note the effective dates and the structured separation payments when considering any near-term impacts on corporate governance costs and executive continuity.